Related references
Note: Only part of the references are listed.Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation
Xin Chen et al.
MOLECULAR THERAPY (2021)
Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay
Karina Krotova et al.
HUMAN GENE THERAPY (2020)
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Erik Allen Lykken et al.
JOURNAL OF NEURODEVELOPMENTAL DISORDERS (2018)
Neuraminidase-mediated desialylation augments AAV9-mediated gene expression in skeletal muscle
Hongling Zhu et al.
JOURNAL OF GENE MEDICINE (2018)
Gene therapy for neurological disorders: progress and prospects
Benjamin E. Deverman et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems
Ken Y. Chan et al.
NATURE NEUROSCIENCE (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens
Sarah C. Nicolson et al.
JOURNAL OF VIROLOGY (2016)
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Benjamin E. Deverman et al.
NATURE BIOTECHNOLOGY (2016)
Aspartylglycosaminuria: a review
Maria Arvio et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Random Splicing of Several Exons Caused by a Single Base Change in the Target Exon of CRISPR/Cas9 Mediated Gene Knockout
Marcel Kapahnke et al.
CELLS (2016)
Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria
Antje Banning et al.
SCIENTIFIC REPORTS (2016)
Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System
Amine Meliani et al.
HUMAN GENE THERAPY METHODS (2015)
Differential Adeno-Associated Virus Serotype-Specific Interaction Patterns with Synthetic Heparins and Other Glycans
Mario Mietzsch et al.
JOURNAL OF VIROLOGY (2014)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype
Brian L. Ellis et al.
VIROLOGY JOURNAL (2013)
Glycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9
Shen Shen et al.
JOURNAL OF VIROLOGY (2012)
Identification of the Galactose Binding Domain of the Adeno-Associated Virus Serotype 9 Capsid
Christie L. Bell et al.
JOURNAL OF VIROLOGY (2012)
Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors
Steven J. Gray et al.
HUMAN GENE THERAPY (2011)
Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9
Shen Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Christie L. Bell et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates
Steven J. Gray et al.
MOLECULAR THERAPY (2011)
Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons
Sandra Duque et al.
MOLECULAR THERAPY (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2009)
α2,3 and α2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6
Zhijian Wu et al.
JOURNAL OF VIROLOGY (2006)
Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line
ES Mohammadi et al.
NUCLEIC ACIDS RESEARCH (2004)
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding
SR Opie et al.
JOURNAL OF VIROLOGY (2003)
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
DM McCarty et al.
GENE THERAPY (2003)
Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis
DM McCarty et al.
GENE THERAPY (2001)
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity
N Kaludov et al.
JOURNAL OF VIROLOGY (2001)
Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors
CL Halbert et al.
JOURNAL OF VIROLOGY (2001)
Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors
A Handa et al.
JOURNAL OF GENERAL VIROLOGY (2000)
Share Paper
